Skip to main
INAB
INAB logo

IN8BIO (INAB) Stock Forecast & Price Target

IN8BIO (INAB) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 0%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

IN8bio Inc demonstrates a positive outlook due to the promising efficacy of its lead product candidate, INB-100, which has shown a 100% overall survival rate at one year in high-risk acute myeloid leukemia (AML) patients undergoing haploidentical stem cell transplantation, significantly surpassing the historical 70% survival rate. The company’s ongoing multi-center expansion cohort study is expected to further validate these results, as it enrolls more patients and aims for completion in 2025. Additionally, the favorable safety profile of INB-100, with no reported treatment-related deaths or severe side effects, bolsters investor confidence in the product's potential for successful commercialization.

Bears say

IN8bio Inc's outlook is negatively impacted by a reduced price target of $6.00, down from $8.00, indicating diminished investor confidence in the company's financial prospects. Despite some potential shown by INB-619 in preclinical studies, the overall commercial viability of its gamma-delta T cell product candidates faces significant uncertainty, particularly given the competitive landscape in oncology. Furthermore, the company's reliance on early-stage product candidates, such as INB-400 and INB-100, contributes to heightened financial risks associated with clinical trial outcomes and long-term market acceptance.

IN8BIO (INAB) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IN8BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IN8BIO (INAB) Forecast

Analysts have given IN8BIO (INAB) a Strong Buy based on their latest research and market trends.

According to 7 analysts, IN8BIO (INAB) has a Strong Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IN8BIO (INAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.